ภาษาไทย
English
Thai Newswire - ไทย นิวส์ไวร์
Newswire
PR Newswire - /DISREGARD RELEASE: Celltrion USA/
We are advised by Celltrion USA that journalists and other readers should disregard the news release, Celltrion USA partners with Express Scripts and Cigna Healthcare to expand access to ZYMFENTRA® (infliximab-dyyb), the first and only FDA-approved subcutaneous infliximab on their medical benefit formulary, issued 28-Aug-2024 over PR Newswire.
The information provided in this article was created by CISION PR Newswire, our news partner. The author's opinions and the content shared on this page are their own and may not necessarily represent the perspectives of Thai Newswire.
Comment